Skip to content

Role of Homoeopathic Medicine in the management of Adenoid Hypertrophy in Children

Effectiveness of Individualised Homoeopathic Medicine in management of Adenoid Hypertrophy in Children- A Prospective Single Arm Clinical Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094436
Enrollment
40
Registered
2025-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J352- Hypertrophy of adenoids

Interventions

Intervention1: Individualised Homoeopathic Medicine : In this study, the intervention will consist of individualised homoeopathic treatment prescribed on the basis of detailed case taking, analysis, e

Sponsors

Nehru Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children between 3 to 10 years of age, clinically diagnosed with adenoid hypertrophy and presenting with symptoms such as nasal obstruction, mouth breathing, or snoring, will be included in the study. Only those cases with radiological confirmation showing an Adenoid?Nasopharynx (A/N) ratio greater than 0.5 will be enrolled. Participation will be limited to children whose parents or guardians give informed consent and are willing to opt for non-surgical homoeopathic management.

Exclusion criteria

Exclusion criteria: Children requiring emergency adenoidectomy or those with severe complications such as obstructive sleep apnoea with an A/N ratio above 0.75 will be excluded from the study. Patients with structural abnormalities like deviated nasal septum, cleft palate, or nasal polyps, as well as those with immunodeficiency or chronic systemic illnesses, will not be included. Children with psychiatric or behavioral disorders, a previous history of adenoidectomy, or those receiving concurrent treatment from other medical systems for adenoid hypertrophy will also be excluded. Additionally, refusal to participate or non-compliance with treatment and follow-up will lead to exclusion.

Design outcomes

Primary

MeasureTime frame
1.Adenoid?Nasopharynx (A/N) ratio on lateral nasopharyngeal X-ray 2.Nasal Obstruction Symptom Evaluation (NOSE) scoreTimepoint: At Baseline and after 6 months of Treatment

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Mansi Aggarwal

Nehru Homoeopathic Medical College and Hospital

drbipin.jethani@gmail.com9810146343

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026